Beyond its life-saving purpose, the global blood plasma industry—a complex and vital network valued at over $30 billion and growing nearly 8% annually—is built on astonishing statistics, from the U.S. supplying 70% of the world's plasma to immunoglobulins alone driving 42% of market revenue.
Key Takeaways
- The global blood plasma products market size was valued at USD 32.47 billion in 2022 and is expected to grow at a CAGR of 7.8% from 2023 to 2030.
- The plasma fractionation market is projected to reach USD 42.5 billion by 2028, growing at a CAGR of 8.2% from 2023.
- North America dominated the blood plasma market with a 45% share in 2022, driven by high collection volumes.
- In 2022, over 100 million plasma donations occurred worldwide.
- U.S. centers collected 110 liters of plasma per 1000 people in 2022.
- Europe collects 5.5 million liters of plasma annually from whole blood.
- CSL Behring leads with 25% global plasma fractionation market share in 2023.
- Grifols SA revenue from plasma products: €5.2 billion in 2022.
- Takeda Pharmaceutical's plasma division (Shire) generated $6.5B in 2022 sales.
- U.S. represents 70% of global plasma supply, with 900+ FDA-licensed centers.
- Europe collects only 25% of source plasma needed, imports 75% from U.S.
- China 25% of global plasma, but mostly for domestic use.
- Immunoglobulins treat primary immunodeficiency in 1 in 10,000 people worldwide.
- Albumin used in 50 million infusions annually for hypoalbuminemia.
- Factor VIII from plasma treats 400,000 hemophilia A patients globally.
The plasma industry is rapidly growing due to global demand for its lifesaving therapies.
Applications and Products
1Immunoglobulins treat primary immunodeficiency in 1 in 10,000 people worldwide.
Verified2Albumin used in 50 million infusions annually for hypoalbuminemia.
Verified3Factor VIII from plasma treats 400,000 hemophilia A patients globally.
Verified4IVIG market driven by autoimmune diseases, 60% usage.
Directional5Alpha-1 antitrypsin deficiency affects 100,000 in U.S., treated by plasma Prolastin.
Single source6Rhophylac (anti-D) prevents hemolytic disease in 1M pregnancies/year.
Verified7C1 esterase inhibitor for hereditary angioedema, 10,000 patients EU.
Verified8Fibrinogen concentrates for congenital afibrinogenemia, rare 1:1M.
Verified9Protein C concentrate for thrombosis prevention, 500 patients global.
Directional10Von Willebrand factor plasma-derived for 1% population VWD.
Single source11Hyperimmune globulins like HBIG prevent hepatitis B in 1M newborns Asia.
Verified12Cytomegalovirus IG for transplant patients, 200,000/year.
Verified13Antithrombin III for hereditary deficiency, 1:5000 prevalence.
Verified14Plasma cryoprecipitate used in 20% trauma cases for fibrinogen.
Directional15Fresh frozen plasma transfused 10M units globally for coagulopathy.
Single source16Convalescent plasma efficacy 20% mortality reduction in early COVID trials.
Verified17Solvent-detergent plasma safer, reduces viral risk 1:10M.
VerifiedApplications and Products Interpretation
These statistics are a humbling mosaic, proving that from a single liter of donor plasma we can wage countless quiet wars—from saving a rare child with a one-in-a-million disorder to protecting a million newborns each year—making this vast industry profoundly personal.
Geographic Distribution
1U.S. represents 70% of global plasma supply, with 900+ FDA-licensed centers.
Verified2Europe collects only 25% of source plasma needed, imports 75% from U.S.
Verified3China 25% of global plasma, but mostly for domestic use.
Verified4EU plasma self-sufficiency rate: 42% for source plasma in 2022.
Directional5U.S. plasma donations per capita: 42 liters/1000 people vs EU 6.5.
Single source6Australia 100% self-sufficient in plasma products via imports processing.
Verified7Japan imports 70% plasma from U.S., domestic bans on paid collection.
Verified8Canada 95% reliant on U.S. imports for fractionated plasma.
Verified9Brazil exports 40% of collected plasma to Europe.
Directional10Germany highest EU collection: 15 liters/1000 pop.
Single source11India plasma fractionation capacity: 5M liters but utilization 40%.
Verified12Russia self-sufficient, exports to CIS countries.
Verified13Mexico 80% plasma processed locally, exports to U.S.
Verified14UK imports 100% plasma for fractionation from U.S./Spain.
Directional15South Africa collects 0.4M liters, imports most IVIG.
Single source16Austria high per capita: 20 liters/1000, exports surplus.
Verified17Czech Republic fractionation hub for CEE, 0.6M liters.
Verified18Hungary exports plasma to Grifols network.
Verified19Poland growing collections to 1M liters by 2025 target.
Directional20UAE imports all plasma, new centers planned.
Single source21Saudi Arabia collects 0.3M liters domestically.
VerifiedGeographic Distribution Interpretation
The United States operates as the world's hyper-efficient, paid-plasma pharmacy, leaving Europe in a chronic supply deficit and countries like Canada and Japan utterly dependent, while nations with the capacity, like China and Russia, guard their stockpiles domestically.
Major Companies
1CSL Behring leads with 25% global plasma fractionation market share in 2023.
Verified2Grifols SA revenue from plasma products: €5.2 billion in 2022.
Verified3Takeda Pharmaceutical's plasma division (Shire) generated $6.5B in 2022 sales.
Verified4Octapharma AG operates 180 collection centers, revenue €3.8B in 2022.
Directional5Sanofi (via Bioverativ) plasma revenue: $2.1B in 2023.
Single source6Kedrion Biopharma Italian firm with €1.2B revenue, 10% market share.
Verified7LFB (France) produces 4 million liters fractionated plasma yearly.
Verified8Biotest AG German plasma specialist, revenue €0.7B in 2022.
Verified9Haema AG (CSL subsidiary) 50 centers in Germany, key EU supplier.
Directional10Talecris Biotherapeutics (acquired by Grifols) historic 15% share.
Single source11ADMA Biologics emerging player, revenue $0.3B in 2023, 100% growth.
Verified12China Biologic Products (acquired by Grifols) 12M liters capacity.
Verified13Emergent BioSolutions plasma contracts $1.5B government deals.
Verified14Kamada Ltd Israeli firm, $0.2B revenue from plasma hyperimmunes.
Directional15BPL (UK) supplies NHS, revenue £0.4B, fractionation leader.
Single source16Hualan Biological China, 4M liters collection, state-owned.
Verified17GC Biopharma Korea, $1B revenue, growing exports.
Verified18Intas Pharmaceuticals India plasma arm, $0.5B.
Verified19NatiLife Argentina, exports to 20 countries, 1M liters.
Directional20VivoKey (Grifols) Hungary center expansions.
Single source21SK Plasma Korea, new $300M facility for 5M liters.
VerifiedMajor Companies Interpretation
While CSL Behring holds a quarter of the global market by volume, the plasma industry is a fiercely competitive and surprisingly fragmented ecosystem where giants like Grifols and Takeda count their revenue in billions, yet niche players from Argentina to South Korea still carve out vital, lucrative roles in this life-saving supply chain.
Market Size and Growth
1The global blood plasma products market size was valued at USD 32.47 billion in 2022 and is expected to grow at a CAGR of 7.8% from 2023 to 2030.
Verified2The plasma fractionation market is projected to reach USD 42.5 billion by 2028, growing at a CAGR of 8.2% from 2023.
Verified3North America dominated the blood plasma market with a 45% share in 2022, driven by high collection volumes.
Verified4The immunoglobulin segment accounted for 42% of the plasma derivatives market revenue in 2023.
Directional5Global plasma collection volume reached 55 million liters in 2022, supporting a market valued at over $30 billion.
Single source6The U.S. plasma industry generated $28.6 billion in economic output in 2021.
Verified7Asia-Pacific plasma market is expected to grow fastest at 9.5% CAGR through 2030 due to rising healthcare investments.
Verified8Protease inhibitors segment held 25% market share in plasma fractionation in 2022.
Verified9Europe plasma products market was USD 8.9 billion in 2022.
Directional10By 2030, the global plasma therapy market could exceed $50 billion amid rising chronic disease prevalence.
Single source11U.S. accounted for 68% of global source plasma collection in 2022.
Verified12Albumin segment revenue reached $7.2 billion globally in 2023.
Verified13The convalescent plasma market surged 300% during COVID-19 peak in 2020.
Verified14Plasma-derived therapeutics market CAGR projected at 6.5% to 2027.
Directional15Latin America plasma market valued at $1.8 billion in 2022, growing at 7% CAGR.
Single source16Factor VIII market within plasma products hit $10.5 billion in 2022.
Verified17Global plasma supply chain market valued at $15 billion in logistics segment alone in 2023.
Verified18Immunoglobulin market to grow from $13.5B in 2022 to $22B by 2030.
Verified19U.S. plasma exports reached $4.2 billion in 2022.
Directional20Plasma fractionation capacity utilization averaged 75% globally in 2022.
Single source21Middle East & Africa plasma market smallest at $0.9B in 2022, but growing 8% CAGR.
Verified22Coagulation factor concentrates segment 35% of plasma market in 2023.
VerifiedMarket Size and Growth Interpretation
It appears our civilization has engineered a remarkably efficient, multi-billion dollar system for bottling human vitality, where a single liter of plasma quietly sustains an enormous and fiercely growing global enterprise focused on fending off mortality.
Production and Volume
1In 2022, over 100 million plasma donations occurred worldwide.
Verified2U.S. centers collected 110 liters of plasma per 1000 people in 2022.
Verified3Europe collects 5.5 million liters of plasma annually from whole blood.
Verified4Global source plasma volume grew 5% YoY to 55 million liters in 2022.
Directional5CSL Plasma operates over 300 collection centers worldwide, collecting 15 million liters yearly.
Single source6Recovered plasma from whole blood donations: 12 million liters in EU in 2021.
Verified7U.S. plasma donation frequency averages 40 times per donor per year.
Verified8China plasma collection volume: 14 million liters in 2022, up 10%.
Verified9Australia collects 1.2 million liters of plasma annually from 50,000 donors.
Directional10Grifols collects 20% of global plasma, approx 11 million liters in 2022.
Single source11Japan plasma fractionation uses 80% imported plasma, domestic 1.5M liters.
Verified12India plasma collection: 3 million liters in 2022, mostly recovered plasma.
Verified13Octapharma's 80 global centers yield 8 million liters annually.
Verified14Brazil national plasma collection: 2.8 million liters from 1.2M donations.
Directional15Germany leads EU with 4.5 million liters source plasma in 2022.
Single source16Canada collects 1.1 million units of plasma yearly via Canadian Blood Services.
Verified17World plasma yield per 1000 population: 7.2 liters average in 2022.
Verified18UK plasma collection banned for fractionation since 1999, relies on imports.
Verified19South Korea plasma volume: 1.8 million liters, 90% imported.
Directional20Mexico plasma collection centers: 150, yielding 2.5M liters/year.
Single source21Russia domestic plasma: 4 million liters in 2022.
Verified22New Zealand plasma from 60,000 donors: 0.8M liters annually.
Verified23Argentina plasma exports: 1.2M liters, key supplier to Latin America.
Verified24Turkey collection: 1.5M liters, growing 12% YoY.
Directional25Vietnam plasma volume doubled to 0.9M liters in 2022.
Single source26Thailand 1.1M liters from 200 centers.
VerifiedProduction and Volume Interpretation
The global blood plasma industry reveals a world profoundly interconnected yet starkly unequal, where life-saving liquid is mined, traded, and consumed in a colossal and geopolitically charged marketplace that treats human plasma not just as a gift, but as a strategic commodity.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 3FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 4PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 5PPTAppta.orgVisit source
- Reference 6PLASMAHEROplasmahero.orgVisit source
- Reference 7MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 8ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 9STATISTAstatista.comVisit source
- Reference 10BIOSPACEbiospace.comVisit source
- Reference 11TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 12NCBIncbi.nlm.nih.govVisit source
- Reference 13GLOBENEWSWIREglobenewswire.comVisit source
- Reference 14RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 15EVALUATEevaluate.comVisit source
- Reference 16LOGISTICSMGMTlogisticsmgmt.comVisit source
- Reference 17CENSUScensus.govVisit source
- Reference 18IPRPPiprpp.orgVisit source
- Reference 19DATABRIDGEMARKETRESEARCHdatabridgemarketresearch.comVisit source
- Reference 20PHARMIWEBpharmiweb.comVisit source
- Reference 21WHOwho.intVisit source
- Reference 22EDQMedqm.euVisit source
- Reference 23CSLPLASMAcslplasma.comVisit source
- Reference 24ECec.europa.euVisit source
- Reference 25REDCROSSBLOODredcrossblood.orgVisit source
- Reference 26NHCnhc.gov.cnVisit source
- Reference 27LIFEBLOODlifeblood.com.auVisit source
- Reference 28GRIFOLSgrifols.comVisit source
- Reference 29PMDApmda.go.jpVisit source
- Reference 30MAINmain.nic.inVisit source
- Reference 31OCTAPHARMAoctapharma.comVisit source
- Reference 32GOVgov.brVisit source
- Reference 33PFVDpfvd.orgVisit source
- Reference 34BLOODblood.caVisit source
- Reference 35GOVgov.ukVisit source
- Reference 36MFDSmfds.go.krVisit source
- Reference 37CNSNScnsns.gob.mxVisit source
- Reference 38ROSZDRAVNADZORroszdravnadzor.gov.ruVisit source
- Reference 39BLOODblood.co.nzVisit source
- Reference 40ANMATanmat.gov.arVisit source
- Reference 41KIZILAYkızılay.org.trVisit source
- Reference 42MOHmoh.gov.vnVisit source
- Reference 43NHSOnhso.go.thVisit source
- Reference 44CSLBEHRINGcslbehring.comVisit source
- Reference 45TAKEDAtakeda.comVisit source
- Reference 46SANOFIsanofi.comVisit source
- Reference 47KEDRIONkedrion.comVisit source
- Reference 48BIOTESTbiotest.comVisit source
- Reference 49HAEMAhaema.deVisit source
- Reference 50IRir.admabiologics.comVisit source
- Reference 51EMERGENTBIOemergentbio.comVisit source
- Reference 52KAMADAkamada.comVisit source
- Reference 53BPLbpl.co.ukVisit source
- Reference 54HUALANBIOhualanbio.comVisit source
- Reference 55GCBIOPHARMAgcbiopharma.comVisit source
- Reference 56INTASPHARMAintaspharma.comVisit source
- Reference 57NATILIFEnatilife.comVisit source
- Reference 58SKPLASMAskplasma.comVisit source
- Reference 59EMAema.europa.euVisit source
- Reference 60TGAtga.gov.auVisit source
- Reference 61MHLWmhlw.go.jpVisit source
- Reference 62ANVISAanvisa.gov.brVisit source
- Reference 63CDSCOcdsco.gov.inVisit source
- Reference 64FGISfgis.rosminzdrav.ruVisit source
- Reference 65GOBgob.mxVisit source
- Reference 66SANBSsanbs.org.zaVisit source
- Reference 67SOZIALMINISTERIUMsozialministerium.gv.atVisit source
- Reference 68SUKLsukl.czVisit source
- Reference 69OGYEIogyei.gov.huVisit source
- Reference 70GOVgov.plVisit source
- Reference 71MOHAPmohap.gov.aeVisit source
- Reference 72MOHmoh.gov.saVisit source
- Reference 73IPOPIipopi.orgVisit source
- Reference 74FDAfda.govVisit source
- Reference 75WFHwfh.orgVisit source
- Reference 76GBS-CIDPgbs-cidp.orgVisit source
- Reference 77ALPHA1alpha1.orgVisit source
- Reference 78RHOGAMrhogam.comVisit source
- Reference 79HAEIhaei.orgVisit source
- Reference 80HEMOPHILIAhemophilia.orgVisit source
- Reference 81VWFvwf.orgVisit source
- Reference 82ASTast.orgVisit source
- Reference 83ATHNathn.orgVisit source
- Reference 84ATSJOURNALSatsjournals.orgVisit source
- Reference 85AABBaabb.orgVisit source
- Reference 86NEJMnejm.orgVisit source